Skip to main content

  • Magmaris Resorbable Magnesium Scaffold Versus Conventional Drug-Eluting Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity-Score-Matching Comparison

    • Posted: 10/01/2022
    • Author:

      Quentin de Hemptinne, Panagiotis Xaplanteris, Antoine Guédès, Fabian Demeure, Bert Vandeloo, Christophe Dugauquier, Fabien Picard, David W. Warne, Thomas Pilgrim, Juan F. Iglesias and Johan Bennett

    • CRM2022

    Abstract

    Magmaris® (Biotronik AG, Switzerland) is the first RMS and early experience has shown promising results in stable coronary artery disease. Acute coronary syndromes have been hypothesized as a potential target group for bioresorbable scaffolds, but the efficacy and safety of RMS has not been extensively studied in ST-segment elevation myocardial infarction (STEMI).

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details